Tickers

1. Composite Trajectory Verdict

Given Waystar's subscription/volume-based software model with high recurring revenue, significant debt leverage, and acquisition-driven growth, all three statements carry roughly equal weight: the income statement shows profitability inflection, the cash flow statement reveals operating cash conversion and acquisition funding, and the balance sheet reflects the Iodine acquisition's impact on leverage and goodwill concentration.

Composite Trajectory: Mixed

Earnings are improving decisively: annual revenue grew 16.5% to $1,099.3 million, operating income more than doubled to $249.3 million, and net income swung from a $19.1 million loss to a $112.1 million profit (10-K FY2025). Six-month trends reinforce this with revenue up 20.2% to $633.5 million and net income up 36.9% to $84.2 million (10-Q 2026-06-30). Cash generation is mixed: annual operating cash flow surged 82% to $309.7 million (10-K FY2025), but six-month operating cash flow fell 10.4% to $144.3 million despite higher profits, due to deferred tax timing (10-Q 2026-06-30). The balance sheet is mixed: equity grew 26% to $3.88 billion (10-K FY2025), but total debt rose to $1.48 billion, cash dropped 66% to $61.4 million, and goodwill plus intangibles reached 91.7% of assets (10-K FY2025), while net revenue retention declined to 108.3% from 114.6% (10-Q 2026-06-30).

2. Red Flags

• Net Revenue Retention Rate declined from 114.6% (twelve months ended June 30, 2025) to 108.3% (twelve months ended June 30, 2026) (10-Q 2026-06-30, Key Performance Metrics).
• Six-month operating cash flow decreased 10.4% to $144.3 million despite 20.2% revenue growth and 36.9% net income growth, attributed to deferred federal tax payments in the prior period (10-Q 2026-06-30, Cash Flows).
• GAAP net income ($112.1 million) remains far below Adjusted EBITDA ($462.1 million) for FY2025, a gap driven by $140.5 million depreciation/amortization, $42.1 million stock-based compensation, and $21.1 million acquisition costs (10-K FY2025, Non-GAAP Financial Measures).
• Goodwill and intangible assets represent 91.7% of total assets ($5.31 billion of $5.79 billion) as of December 31, 2025 (10-K FY2025, Critical Accounting Policies).
• Stock-based compensation is recurring and material: $42.1 million in FY2025 and $25.2 million in six months ended June 30, 2026 (10-K FY2025, Note 18; 10-Q 2026-06-30, Non-GAAP reconciliation).
• Six-month investing cash outflow jumped to $182.1 million from $61.7 million, driven by $231.3 million of investment securities purchases (10-Q 2026-06-30, Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Annual revenue increased 16.5% to $1,099.3 million (FY2025 vs FY2024), driven by $100.4 million subscription growth and $54.8 million volume-based growth (10-K FY2025). Operating income more than doubled to $249.3 million from $123.7 million as operating expenses grew only 3.7% despite revenue growth, with depreciation/amortization falling $46.1 million due to fully amortized intangibles (10-K FY2025). Net income swung to $112.1 million from a $19.1 million loss, aided by a $68.7 million reduction in total interest expense after $1.0 billion of debt paydowns in 2024 (10-K FY2025). Six-month results show continued momentum: revenue up 20.2% to $633.5 million, operating income up 20.3% to $156.5 million, and net income up 36.9% to $84.2 million (10-Q 2026-06-30). Subscription revenue remains the primary growth driver, contributing $92.3 million of the six-month increase (10-Q 2026-06-30).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow rose 82% to $309.7 million in FY2025 from $169.8 million in FY2024, reflecting higher profits, lower cash interest payments after debt paydowns, and working capital changes (10-K FY2025). However, six-month operating cash flow declined 10.4% to $144.3 million in 2026 versus $161.0 million in 2025, which the filing attributes to deferred federal tax payments allowed by the IRS in the prior period (10-Q 2026-06-30). Investing cash outflows surged to $680.9 million annually (from $27.3 million) due to the $629.5 million Iodine acquisition, and to $182.1 million for six months (from $61.7 million) driven by $231.3 million of investment securities purchases (10-K FY2025; 10-Q 2026-06-30). Financing cash flows were positive annually ($243.5 million) but minimal in the latest six months ($6.4 million), with the decline partly due to share repurchases and lower employee equity proceeds (10-Q 2026-06-30).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets grew 26.4% to $5.79 billion at December 31, 2025 from $4.58 billion at December 31, 2024, primarily from the Iodine acquisition adding $997 million of goodwill and $367 million of intangible assets (10-K FY2025, Note 7). By June 30, 2026, total assets were $5.79 billion, roughly flat from year-end (10-Q 2026-06-30 XBRL). Total debt increased to $1.48 billion at December 31, 2025 from $1.24 billion, with the First Lien Term Loan at $1.40 billion and the Receivables Facility at $80 million (10-K FY2025, Note 13). Cash and equivalents fell to $61.4 million from $182.1 million, while investment securities rose to $179.0 million by June 30, 2026 from $24.9 million at December 31, 2025 (10-K FY2025; 10-Q 2026-06-30). Stockholders' equity grew 26% to $3.88 billion, supported by $620.8 million of common stock issued for the Iodine acquisition and $25.8 million from employee equity plans (10-K FY2025). Goodwill and intangibles constitute 91.7% of assets, indicating high acquisition-related asset concentration (10-K FY2025).

6. Data Gaps

• Full quarterly income statements for Q1 2026, Q3 2025, and Q4 2025 are not provided in the excerpts; only six-month and Q2 figures are available for 2026.
• FY2026 full-year results are not yet available.
• Free cash flow (operating cash flow less capital expenditures) is not explicitly reported; capex is shown only in aggregate with capitalized software ($26.5 million for six months ended June 2026).
• Segment-level profitability or revenue breakdown beyond subscription/volume-based/provider-patient split is not provided (single segment).
• Detailed debt maturity schedule beyond the five-year summary in the 10-K is not in the quarterly filings.
• The 10-Q for March 31, 2026 and September 30, 2025 are listed as provided but their full financial statement content is not included in the excerpts.